| Phase 18 trials |
|
Phase 1
|
NCT07471217 |
Apr → May 2026 |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07394309 |
Feb 2026 overdue |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07263152 |
Dec 2025 → Feb 2026 |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07262333 |
Dec 2025 → Jul 2026 overdue |
chronic kidney disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07262346 |
Dec 2025 → May 2026 |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04162821 |
Oct → Nov 2019 |
— |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04123769 |
Sep 2019 → Oct 2020 |
chronic hepatitis B virus infection |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04124081 |
May → Jun 2019 |
— |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
| Phase 23 trials · 1 met primary |
|
Phase 2
|
NCT07417553 |
Apr → Jul 2026 overdue |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07364448 |
Mar → Jul 2026 overdue |
chronic hepatitis B virus infection |
Beijing Continent Pharmaceutical Co, Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT02499562 |
Jun 2015 → Nov 2020 |
chronic hepatitis B virus infection |
Shanghai Genomics, Inc. |
Completed
|
Met primary
|
| Phase 34 trials |
|
Phase 3
|
NCT07343778 |
Mar → Oct 2026 expected |
chronic hepatitis B virus infection |
Beijing Continent Pharmaceutical Co, Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07412236 |
Jan 2026 → Dec 2028 expected |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05905172 |
Aug 2023 → Jun 2028 expected |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05115942 |
Dec 2021 → Oct 2024 |
fibrotic liver disease |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT04125056 |
Jan 2019 |
— |
Beijing Continent Pharmaceutical Co, Ltd. |
Completed
|
No outcome recorded
|